Top

Published in:

01-05-2010 | Preclinical study

Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation

Authors: Jane Wenzel, Reiner Zeisig, Wolfram Haider, Sylvia Habedank, Iduna Fichtner

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

The process of metastasis formation in cancer is not completely understood and is the main reason cancer therapies fail. Previously, we showed that dual liposomes simultaneously containing the hemostatic inhibitor, dipyridamole and the anticancer drug, perifosine potently inhibited metastasis, causing a 90% reduction in the number of lung metastases in a murine experimental metastasis model. To gain deeper insight into the mechanisms leading to the inhibition of metastasis by these dual liposomes, in the present study, the development of metastases by MT3 breast cancer cells in a mouse xenograft model was analyzed in more detail with regard to tumor cell settlement and metastatic growth. We found that the development of lung metastases by MT3 tumor cells is essentially dependent on the formation of fibrin clots as a precondition for the pulmonary arrest of tumor cells and the subsequent intravascular expansion of micrometastases before their invasion into the surrounding tissue.

Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50:6130–6138PubMed

Price JT, Thompson EW (2002) Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 6:217–233CrossRefPubMed

Tsuruo T, Fujita N (2008) Platelet aggregation in the formation of tumor metastasis. Proc Jpn Acad Ser B Phys Biol Sci 84:189–198CrossRefPubMed

Khanna C, Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26:513–523CrossRefPubMed

Honn KV, Tang DG, Crissman JD (1992) Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 11:325–351CrossRefPubMed

Felding-Habermann B (2003) Targeting tumor cell–platelet interaction in breast cancer metastasis. Pathophysiol Haemost Thromb 33(Suppl 1):56–58CrossRefPubMed

Borsig L (2008) The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 8:1247–1255CrossRefPubMed

Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 54:75–84CrossRef

Borsig L, Wong R, Feramisco J et al (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 98:3352–3357CrossRefPubMed

10.

Kannagi R (1997) Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J 14:577–584CrossRefPubMed

11.

Trousseau A (1865) Phlegmasia alba dolens. In: Clinique Medicale de l’Hotel Dieu de Paris, vol 3. Paris, JB Balliere et Fils, Paris, France, pp 654–712

12.

Tohgo A, Tanaka NG, Ogawa H (1986) Platelet-aggregating activities of metastasizing tumor cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization. Invasion Metastasis 6:58–68PubMed

13.

Nieswandt B, Hafner M, Echtenacher B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed

14.

Gupta GP, Massague J (2004) Platelets and metastasis revisited: a novel fatty link. J Clin Invest 114:1691–1693PubMed

15.

Al-Mehdi AB, Tozawa K, Fisher AB et al (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6:100–102CrossRefPubMed

16.

Saiki I, Koike C, Obata A et al (1996) Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor-cell arrest in lungs followed by extravasation. Int J Cancer 65:833–839CrossRefPubMed

17.

Kragh M, Loechel F (2005) Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review). Int J Oncol 27:1159–1167PubMed

18.

Hejna M, Raderer M, Zielinski CC (1999) Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91:22–36CrossRefPubMed

19.

Bobek V, Kovarik J (2004) Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 58:213–219CrossRefPubMed

20.

Mancuso A, Sternberg CN (2006) New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 16:337–341CrossRefPubMed

21.

Gosk S, Gottstein C, Bendas G (2005) Targeting of immunoliposomes to endothelial cells expressing VCAM: a future strategy in cancer therapy. Int J Clin Pharmacol Ther 43:581–582PubMed

22.

Kessner S, Krause A, Rothe U (2001) Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells. Biochim Biophys Acta 1514:177–190CrossRefPubMed

23.

Zeisig R, Stahn R, Wenzel K et al (2004) Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro. Biochim Biophys Acta 1660:31–40CrossRefPubMed

24.

Keil C, Zeisig R, Fichtner I (2005) Effect of surface modified liposomes on the aggregation of platelets and tumor cells. Thromb Haemost 94:404–411PubMed

25.

Borsig L, Wong R, Hynes RO (2002) Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A 99:2193–2198CrossRefPubMed

26.

Wenzel J, Zeisig R, Fichtner I (2009) Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. Int J Pharm 370:121–128CrossRefPubMed

27.

Naundorf H, Rewasowa EC, Fichtner I (1992) Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. Breast Cancer Res Treat 23:87–95CrossRefPubMed

28.

Cardinal DC, Flower RJ (1980) The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 3:135–158CrossRefPubMed

29.

Ottewell PD, Coleman RE, Holen I (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 96:101–113CrossRefPubMed

30.

Fantozzi A, Christofori G (2006) Mouse models of breast cancer metastasis. Breast Cancer Res 8:212CrossRefPubMed

31.

Im JH, Fu W, Wang H et al (2004) Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64:8613–8619CrossRefPubMed

32.

Gasic GJ (1984) Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 3:99–114CrossRefPubMed

33.

Beviglia L, Stewart GJ, Niewiarowski S (1995) Effect of four disintegrins on the adhesive and metastatic properties of B16F10 melanoma cells in a murine model. Oncol Res 7:7–20PubMed

34.

Oleksowicz L, Mrowiec Z, Schwartz E (1995) Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res 79:261–274CrossRefPubMed

35.

Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185CrossRefPubMed

36.

Wong CW, Song C, Grimes MM et al (2002) Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol 161:749–753PubMed

37.

Tao K, Fang M, Alroy J et al (2008) Imageable 4T1 model for the study of late stage breast cancer. BMC Cancer 8:228CrossRefPubMed

38.

DuPre’ SA, Hunter KW Jr (2007) Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol 82:12–24CrossRefPubMed

Title: Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation
Authors: Jane Wenzel
Reiner Zeisig
Wolfram Haider
Sylvia Habedank
Iduna Fichtner
Publication date: 01-05-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0448-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis

Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures

Are PALB2 mutations associated with increased risk of male breast cancer?

Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?

Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer